Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc.

Biotechnology Research 395 Oyster Point Blvd. 31 employees
Employees
31

Sunesis Pharmaceuticals, Inc. Overview

Headquarters
395 Oyster Point Blvd.
Phone Number
Available in AeroLeads
Website
sunesis.com
Industry
Biotechnology Research
Employees
31
Founded
1987
Funding
25.0M
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords

About Sunesis Pharmaceuticals, Inc.

Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers

Sunesis Pharmaceuticals, Inc. Contact Details

Employees by Management Level

Individual contributor 11 profiles
Manager 3 profiles
Associate / junior 3 profiles
Executive 1 profile
Senior / Lead 1 profile

Department Contact Coverage

Department Contacts Email Phone
General 9 9 1
Sales 4 4 0
HR 1 1 1
Healthcare 1 1 0
Executive 1 1 0
Marketing 1 1 0

Sunesis Pharmaceuticals, Inc. Tech Stack

Data / AI 2 profiles
Engineering 2 profiles

Compare Similar Companies to Sunesis Pharmaceuticals, Inc.